Population survey on myeloma and lymphoma cancer
Article
|Published
People who have been diagnosed with myeloma or lymphoma are now given the opportunity to report on their health and quality of life shortly after diagnosis, and then again one and three years later.
It can be burdensome to live with late effects after cancer treatment, and it is important for the patient group that we get an overview of the burden and duration of late effects, and how these affect the quality of life.
Mapping of late effects
Through the population survey, the health and quality of life of individuals both with and without these forms of cancer will be mapped. This will provide us with knowledge about how common different late effects are, and who is affected, for instance based on the treatment they have received. Since individuals without cancer are also invited, we will gain more knowledge about which ailments are more common in the general population that may be due to, for example, aging, and which ailments can be linked to cancer and cancer treatment.
Questionnaire
We use translations of validated questionnaires from European Organisation for Research and Treatment of Cancer (EORTC) (www.eortc.org), samt Functional Assessment of Cancer Therapy (FACT)-Lym (www.facit.org) in the survey.
Who can participate?
Individuals diagnosed with myeloma or lymphoma from July 1, 2023, will receive an invitation to participate.